切换至 "中华医学电子期刊资源库"

中华危重症医学杂志(电子版) ›› 2024, Vol. 17 ›› Issue (02) : 136 -139. doi: 10.3877/cma.j.issn.1674-6880.2024.02.008

短篇论著

ω-3鱼油脂肪乳注射液在脓毒症患者中的应用:前瞻性、随机对照、先导试验
冯芳1,(), 陈宇1, 杨静1, 满珂1, 蔡红燕1, 李群1   
  1. 1. 730030 兰州,兰州大学第二医院重症医学科
  • 收稿日期:2023-08-25 出版日期:2024-04-30
  • 通信作者: 冯芳
  • 基金资助:
    甘肃省自然科学基金项目(23JRRA0965); 兰州大学第二医院(第二临床医学院)"萃英科技创新"计划项目(CY2021-BJ-A10)

Application of omega-3 fish oil fat emulsion injection in patients with sepsis: a prospective, randomized controlled, and pilot trial

Fang Feng(), Yu Chen, Jing Yang   

  • Received:2023-08-25 Published:2024-04-30
  • Corresponding author: Fang Feng
引用本文:

冯芳, 陈宇, 杨静, 满珂, 蔡红燕, 李群. ω-3鱼油脂肪乳注射液在脓毒症患者中的应用:前瞻性、随机对照、先导试验[J]. 中华危重症医学杂志(电子版), 2024, 17(02): 136-139.

Fang Feng, Yu Chen, Jing Yang. Application of omega-3 fish oil fat emulsion injection in patients with sepsis: a prospective, randomized controlled, and pilot trial[J]. Chinese Journal of Critical Care Medicine(Electronic Edition), 2024, 17(02): 136-139.

目的

评估在脓毒症患者中使用ω-3鱼油脂肪乳注射液作为辅助治疗的临床效果。

方法

前瞻性纳入2023年1月至6月兰州大学第二医院收治的60例脓毒症患者,分为完全胃肠外营养(TPN)组(对照组,30例)与TPN + ω-3鱼油脂肪乳注射液组(试验组,30例)。两组患者入组当天即予以TPN,试验组同时予以10% ω-3鱼油脂肪乳注射液(100 mL/d)输注5 d。收集两组患者的一般资料及输注前、输注后第3天和第5天炎症介质白细胞介素6(IL-6)、IL-8、肿瘤坏死因子α(TNF-α)、C反应蛋白(CRP)水平。

结果

试验组患者ICU住院日显著短于对照组[(5.8 ± 1.3)d vs.(7.5 ± 2.2)d,t = 4.291,P = 0.021]。两组患者输注前及输注后第3天、第5天IL-6、IL-8、TNF-α及CRP水平比较,差异均有统计学意义(F = 4.197、7.961、6.238、5.992,P = 0.032、0.002、0.006、0.021)。进一步两两比较发现,试验组患者输注后第3天和第5天IL-6、IL-8、TNF-α及CRP水平均较同组输注前显著降低,且输注后第5天均更低(P均< 0.05);对照组患者输注后第5天IL-6、IL-8、TNF-α及CRP水平均较同组输注前显著降低(P均< 0.05);此外,试验组患者输注后第5天IL-6、IL-8、TNF-α及CRP水平均较对照组同时间点更低(P均< 0.05)。

结论

ω-3鱼油脂肪乳注射液在脓毒症患者中的应用是有效的,可早期抑制过度的机体炎症反应,从而减轻脓毒症对机体的损害,缩短脓毒症患者ICU住院日。

表1 两组脓毒症患者一般资料比较( ± s
表2 两组脓毒症患者实验室炎症指标比较( ± s
1
Vincent JL. Current sepsis therapeutics[J]. EBioMedicine, 2022 (86): 104318.
2
Lakbar I, Munoz M, Pauly V, et al. Septic shock: incidence, mortality and hospital readmission rates in French intensive care units from 2014 to 2018[J]. Anaesth Crit Care Pain Med, 2022, 41 (3): 101082.
3
Lakbar I, Einav S, Lalevée N, et al. Interactions between gender and sepsis-implications for the future[J]. Microorganisms, 2023, 11 (3): 746.
4
陈敏,袁佳辉,郭冬阳,等. CXC趋化因子配体12/CXC趋化因子受体4轴在脓毒症中的研究进展[J/CD].中华危重症医学杂志(电子版)202013(3):225-228.
5
Zaloga GP. Narrative review of n-3 polyunsaturated fatty acid supplementation upon immune functions, resolution molecules and lipid peroxidation[J]. Nutrients, 2021, 13 (2): 662.
6
Xu B, Xu Z, Xu D, et al. Effect of n-3 polyunsaturated fatty acids on ischemic heart disease and cardiometabolic risk factors: a two-sample Mendelian randomization study[J]. BMC Cardiovasc Disord, 2021, 21 (1): 532.
7
Yan CH, Rathor A, Krook K, et al. Effect of omega-3 supplementation in patients with smell dysfunction following endoscopic sellar and parasellar tumor resection: a multicenter prospective randomized controlled trial[J]. Neurosurgery, 2020, 87 (2): E91-E98.
8
Ying Q Croyal M, Chan DC, et al. Effect of omega-3 fatty acid supplementation on the postprandial metabolism of apolipoprotein (a) in familial hypercholesterolemia[J]. J Atheroscler Thromb, 2023, 30 (3): 274-286.
9
中华医学会肠外肠内营养学分会.鱼油脂肪乳剂临床应用中国专家共识(2022版)[J].中华消化外科杂志202221(10):1313-1325.
10
Yokote K, Niwa K, Hakoda T, et al. Short-term efficacy (at 12 weeks) and long-term safety (up to 52 weeks) of omega-3 free fatty acids (AZD0585) for the treatment of Japanese patients with dyslipidemia-a randomized, double-blind, placebo-controlled, phase III study[J]. Circ J, 2020, 84 (6): 994-1003.
11
Yuan M, Zhang Y, Hua T, et al. Omega-3 polyunsaturated fatty acid supplementation improves lipid metabolism and endothelial function by providing a beneficial eicosanoid-pattern in patients with acute myocardial infarction: a randomized, controlled trial[J]. Clin Nutr, 2021, 40 (2): 445-459.
12
Pontes-Arruda A, Martins LF, de Lima SM, et al. Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study[J]. Crit Care, 2011, 15 (3): R144.
13
Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury[J]. JAMA, 2011, 306 (14): 1574-1581.
14
Sungurtekin H, Degirmenci S, Sungurtekin U, et al. Comparison of the effects of different intravenous fat emulsions in patients with systemic inflammatory response syndrome and sepsis[J]. Nutr Clin Pract, 2011, 26 (6): 665-671.
15
Choudhury A, Kumar M, Sharma BC, et al. Systemic inflammatory response syndrome in acute-on-chronic liver failure: relevance of 'golden window': a prospective study[J]. J Gastroenterol Hepatol, 2017, 32 (12): 1989-1997.
16
Mayer K, Gokorsch S, Fegbeutel C, et al. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis[J]. Am J Respir Crit Care Med, 2003, 167 (10): 1321-1328.
17
Pradelli L, Klek S, Mayer K, et al. Omega-3 fatty acid-containing parenteral nutrition in ICU patients: systematic review with meta-analysis and cost-effectiveness analysis[J]. Crit Care, 2020, 24 (1): 634.
18
田涛,李幼生.脓毒症相关肝损害研究进展[J/CD].中华危重症医学杂志(电子版)202114(2):165-167.
19
Hall TC, Bilku DK, Neal CP, et al. The impact of an omega-3 fatty acid rich lipid emulsion on fatty acid profiles in critically ill septic patients[J]. Prostaglandins Leukot Essent Fatty Acids, 2016 (112): 1-11.
20
Donoghue V, Schleicher GK, Spruyt MGL, et al. Four-oil intravenous lipid emulsion effect on plasma fatty acid composition, inflammatory markers and clinical outcomes in acutely ill patients: a randomised control trial (Foil fact)[J]. Clin Nutr, 2019, 38 (6): 2583-2591.
21
Schwarzkopf KA, Queck A, Thomas D, et al. Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation[J]. PLoS One, 2019 14 (1): e0211537.
22
Kulkarni AV, Anand L, Vyas AK, et al. Omega-3 fatty acid lipid emulsions are safe and effective in reducing endotoxemia and sepsis in acute-on-chronic liver failure: an open-label randomized controlled trial[J]. J Gastroenterol Hepatol, 2021, 36 (7): 1953-1961.
[1] 贾亚娟, 蒙钰铭, 高志伟, 高素敏, 张劲松, 孙虹. 血小板与淋巴细胞比值、降钙素原和白细胞介素6联合检测对脓毒症患者预后价值的研究[J]. 中华危重症医学杂志(电子版), 2024, 17(02): 118-123.
[2] 曹楣汾, 李琼, 凌花, 陆勇, 戴新贵. RETRA评分在ICU收治的创伤患者中的应用[J]. 中华危重症医学杂志(电子版), 2024, 17(02): 130-135.
[3] 柯晴潆, 沈延飞, 许强宏, 蔡国龙. 预测脓毒性心肌病患者院内死亡风险列线图模型的构建及验证[J]. 中华危重症医学杂志(电子版), 2024, 17(01): 10-18.
[4] 刘炯, 彭乐, 马伟, 江斌. 鞘外解剖肝蒂技术治疗肝内胆管细胞癌的疗效评估[J]. 中华普外科手术学杂志(电子版), 2024, 18(04): 373-376.
[5] 王东阳, 林琳, 娄熙彬. SII对局部进展期胃癌nCRT+腹腔镜胃癌根治术后并发症及预后的影响研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(03): 315-318.
[6] 王可, 范彬, 李多富, 刘奎. 两种疝囊残端处理方法在经腹腹膜前腹股沟疝修补术中的疗效比较[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(06): 692-696.
[7] 顾晓凌, 吴冠楠, 宋勇. 核因子E2相关因子2(Nrf2)与铁死亡在脓毒症相关急性肺损伤中的研究进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 324-328.
[8] 胡杰, 蔡国龙. 脓毒症合并低心功能指数患者PiCCO参数的聚类分析[J]. 中华重症医学电子杂志, 2024, 10(01): 25-30.
[9] 黄瑞, 王玉萍, 孙倩, 侯晓红. ICU患者肠内营养并发腹泻最佳证据的审查指标及障碍因素分析[J]. 中华重症医学电子杂志, 2024, 10(01): 38-41.
[10] 吴宗盛, 谢剑锋, 邱海波. 冷诱导RNA结合蛋白与炎症反应的研究进展[J]. 中华重症医学电子杂志, 2024, 10(01): 42-47.
[11] 刘付蓉, 翁利, 杜斌. 2020年至2022年中国重症医学临床研究进展[J]. 中华重症医学电子杂志, 2024, 10(01): 48-53.
[12] 刘霞, 赵双平. TDM指导特重度烧伤脓毒症患者多黏菌素B的个体化治疗一例[J]. 中华重症医学电子杂志, 2024, 10(01): 85-89.
[13] 王丽丽, 张春霞, 申磊, 吴立娜, 潘青, 冯雪. 吗替麦考酚酯联合雷公藤多苷及糖皮质激素治疗对IgA肾病患者肾功能、炎症因子和氧化应激的影响[J]. 中华临床医师杂志(电子版), 2023, 17(12): 1285-1290.
[14] 李琪, 黄钟莹, 袁平, 关振鹏. 基于某三级医院的ICU多重耐药菌医院感染影响因素的分析[J]. 中华临床医师杂志(电子版), 2023, 17(07): 777-782.
[15] 谭睿, 王晶, 於江泉, 郑瑞强. 脓毒症中高密度脂蛋白、载脂蛋白A-I和血清淀粉样蛋白A的作用研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(06): 749-753.
阅读次数
全文


摘要